The Seelos Path

Addressing unmet needs in neurological diseases and disorders and in rare diseases

Advancing multiple late-stage therapeutic candidates for CNS disorders

Developing therapeutics with proven mechanisms of action

Identifying opportunities in large markets

Suicidality in Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD)

  • High area of unmet need
  • No currently approved therapy
  • Fast-acting intranasal administration
  • J&J expects multibillion-dollar opportunity in the underlying depression indication

Sanfilippo Syndrome

  • Pediatric orphan disease also known as MPS disorder
  • Prolonged enhancement of Lysosomal Pathway
  • Promising activity in other orphan indications,
    e.g. OPMD and SCA3

Parkinson’s Disease (PD)

  • Broad spectrum usage possible in both early and late stage PD patients
  • SLS-004: Gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein (α-synuclein)
  • SLS-006: Unique L-Dopa sparing efficacy
  • SLS-007: Peptide-based approach targeting the NACore
  • ~10 million patients worldwide

Rare pediatric disease / Asthma / Other potential targets

PD2 Antagonists:

  • Rare pediatric disease
  • Asthma
  • Unknown indication

Seelos Criteria for Drug Development


  1. Assets must serve a large unmet medical need, orphan population or a unique approach to existing treatments
  2. Assets must possess extensive scientific rationale and/or existing human data
  3. Seelos will look for clinically ready assets or assets where minimal pre-clinical work will be needed
  4. The clinical development pathway should make economic sense and be appropriate for a company our size

Please review our Privacy PolicyTerms of Use, and Accessibility information located at the bottom of this page.